At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALMR Alamar Biosciences
Trading 08-06 09:38:06 EDT
28.55
+0.20
+0.71%
High28.61Low28.42Vol2.16K
Open28.42D1 Closing28.35Amplitude0.67%
Mkt Cap1.98BTradable Cap369.37MTotal Shares69.31M
T/O61.49KT/O Rate0.02%Tradable Shares12.94M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Alamar Biosciences Q2 revenue is expected to decrease by 0.37%, and institutional views are bullish
Earnings Agent  ·  08-03
Earning Preview: Alamar Biosciences Q2 revenue is expected to decrease by 0.37%, and institutional views are bullish
Goldman Sachs-Backed Immunotherapy Pioneer Attovia (ATTO.US) Heads to Nasdaq: Targeting $212.5 Million in Top Funding, Adding Fuel to Biotech IPO Boom
Stock News  ·  07-30
Goldman Sachs-Backed Immunotherapy Pioneer Attovia (ATTO.US) Heads to Nasdaq: Targeting $212.5 Million in Top Funding, Adding Fuel to Biotech IPO Boom
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
GlobeNewswire  ·  07-29
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Alzpath: Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
THOMSON REUTERS  ·  07-23
Alzpath: Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease
Alamar Biosciences Director Ian Ratcliffe Dies; Board Size Reduced to Five
Reuters  ·  07-16
Alamar Biosciences Director Ian Ratcliffe Dies; Board Size Reduced to Five
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
GlobeNewswire  ·  07-15
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
BofA Securities Adjusts Alamar Biosciences Price Target to $30 From $27
MT Newswires Live  ·  07-13
BofA Securities Adjusts Alamar Biosciences Price Target to $30 From $27
Alamar teams with research universities to launch proteomics initiatives
TIPRANKS  ·  07-13
Alamar teams with research universities to launch proteomics initiatives
Alamar Biosciences Launches National Blood Biomarker Initiative for Alzheimer’s Research
Reuters  ·  07-13
Alamar Biosciences Launches National Blood Biomarker Initiative for Alzheimer’s Research
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
GlobeNewswire  ·  07-10
Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
Alamar Biosciences Launches First Multiplexed Blood-based Immunoassay for Emtbr-tau, One of Most Important Biomarkers in Alzheimer's Disease Research
THOMSON REUTERS  ·  07-07
Alamar Biosciences Launches First Multiplexed Blood-based Immunoassay for Emtbr-tau, One of Most Important Biomarkers in Alzheimer's Disease Research
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
GlobeNewswire  ·  07-07
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
Analysts Are Bullish on Top NA Stocks: Alamar Biosciences, Inc. (ALMR), Seaport Therapeutics, Inc. (SPTX)
TIPRANKS  ·  06-09
Analysts Are Bullish on Top NA Stocks: Alamar Biosciences, Inc. (ALMR), Seaport Therapeutics, Inc. (SPTX)
Alamar Biosciences initiated with an Outperform at Leerink
TIPRANKS  ·  05-13
Alamar Biosciences initiated with an Outperform at Leerink
BofA Initiates Alamar Biosciences at Neutral With $27 Price Target
MT Newswires Live  ·  05-12
BofA Initiates Alamar Biosciences at Neutral With $27 Price Target
Alamar Biosciences, Inc. : Bofa Global Research Initiates Coverage With Neutral Rating and Price Objective $27.00
THOMSON REUTERS  ·  05-12
Alamar Biosciences, Inc. : Bofa Global Research Initiates Coverage With Neutral Rating and Price Objective $27.00
Stifel Initiates Alamar Biosciences at Buy With $28 Price Target
MT Newswires Live  ·  05-12
Stifel Initiates Alamar Biosciences at Buy With $28 Price Target
Alamar Biosciences Initiated at Buy by Stifel
Dow Jones  ·  05-12
Alamar Biosciences Initiated at Buy by Stifel
Alamar Biosciences Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $30
THOMSON REUTERS  ·  05-12
Alamar Biosciences Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $30
Alamar Biosciences Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $35
THOMSON REUTERS  ·  05-12
Alamar Biosciences Inc : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $35

Introduction

Company Name.
Alamar Biosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--